<DOC>
	<DOCNO>NCT02704325</DOCNO>
	<brief_summary>The propose clinical trial study rAAVrh74.MCK.GALGT2 duchenne muscular dystrophy ( DMD ) patient involve direct intramuscular injection extensor digitorum brevis muscle ( EDB ) .</brief_summary>
	<brief_title>Gene Transfer Clinical Trial Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2</brief_title>
	<detailed_description>This phase I safety tolerability study . Three DMD subject receive bilateral injection EDB muscle , one EDB receive GALGT2 vector ( rAAVrh74.MCK.GALGT2 ) side receive saline alone ( assign randomize fashion ) . Three subject receive single gene transfer dose 1E12 vector genome , patient investigator blind muscle inject vector . Muscle biopsy perform three month ( 12 week ) two subject 1.5 month ( 6 week ) one subject evaluate blindly expression GALGT2 transgene .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Nonambulant subject , age 9 old Confirmed mutation DMD gene use clinically accept technique completely define mutation A magnetic resonance image EDB show preservation sufficient muscle mass permit transfection Males ethnic group eligible Ability cooperate study procedure Willingness sexually active subject reproductive capacity practice reliable method contraception ( If appropriate ) . Stable dose corticosteroid therapy ( include either prednisone deflazacort generic form ) 12 week prior gene transfer Active viral infection base clinical observation . The presence DMD mutation without weakness loss function Symptoms sign cardiomyopathy , include : Dyspnea exertion , pedal edema , shortness breath upon lie flat , rales base lung Echocardiogram ejection fraction 40 % Serological evidence HIV infection , Hepatitis A , B C infection Diagnosis ( ongoing treatment ) autoimmune disease Persistent leukopenia leukocytosis ( WBC ≤ 3.5 K/µL ≥ 20.0 K/µL ) absolute neutrophil count &lt; 1.5K/µL Concomitant illness requirement chronic drug treatment opinion PI create unnecessary risk gene transfer Subjects rAAVrh74 bind antibody titer ≥ 1:400 determined ELISA immunoassay Presence circulate antiSda antibody determine study approve laboratory . Abnormal laboratory value clinically significant range , base upon normal value Nationwide Children 's Hospital Laboratory</criteria>
	<gender>Male</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DMD</keyword>
	<keyword>Duchenne Muscular Dystrophy</keyword>
</DOC>